Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials

Documenti analoghi

• Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
  di: Ayah Abulehia, et al.
  Pubblicazione: (2026)
• Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials
  di: Doha Jaber, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
  di: Abdur Rafay Bilal, et al.
  Pubblicazione: (2026)
• The Gastrointestinal Safety of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
  di: Ahmed W. Hageen, et al.
  Pubblicazione: (2026)
• Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
  di: A. G. Barajas, et al.
  Pubblicazione: (2025)